Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Amneal Pharmaceuticals (NASDAQ:AMRX) and raises the price target from $8 to $10.
August 13, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Amneal Pharmaceuticals and raises the price target from $8 to $10.
The raised price target from $8 to $10 and the maintained Overweight rating by Barclays is a positive signal for investors, likely leading to a short-term increase in AMRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100